IL161165A0 - Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist - Google Patents
Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonistInfo
- Publication number
- IL161165A0 IL161165A0 IL16116502A IL16116502A IL161165A0 IL 161165 A0 IL161165 A0 IL 161165A0 IL 16116502 A IL16116502 A IL 16116502A IL 16116502 A IL16116502 A IL 16116502A IL 161165 A0 IL161165 A0 IL 161165A0
- Authority
- IL
- Israel
- Prior art keywords
- telmisartan
- same
- sodium salt
- crystalline sodium
- angiotensin antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10153737A DE10153737A1 (de) | 2001-10-31 | 2001-10-31 | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| PCT/EP2002/011394 WO2003037876A1 (de) | 2001-10-31 | 2002-10-11 | Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161165A0 true IL161165A0 (en) | 2004-08-31 |
Family
ID=7704331
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16116502A IL161165A0 (en) | 2001-10-31 | 2002-10-11 | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
| IL161165A IL161165A (en) | 2001-10-31 | 2004-03-30 | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL161165A IL161165A (en) | 2001-10-31 | 2004-03-30 | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1442023B1 (zh) |
| JP (1) | JP5124076B2 (zh) |
| KR (1) | KR100929502B1 (zh) |
| CN (1) | CN100509789C (zh) |
| AR (1) | AR037148A1 (zh) |
| AT (1) | ATE370125T1 (zh) |
| AU (1) | AU2002338886B2 (zh) |
| BR (1) | BR0213568A (zh) |
| CA (1) | CA2463146C (zh) |
| CO (1) | CO5580785A2 (zh) |
| CY (1) | CY1107504T1 (zh) |
| DE (2) | DE10153737A1 (zh) |
| DK (1) | DK1442023T3 (zh) |
| EA (1) | EA007596B1 (zh) |
| EC (1) | ECSP045089A (zh) |
| ES (1) | ES2291505T3 (zh) |
| HK (1) | HK1073841A1 (zh) |
| HR (1) | HRPK20040372B3 (zh) |
| HU (1) | HUP0402391A3 (zh) |
| IL (2) | IL161165A0 (zh) |
| ME (1) | MEP43608A (zh) |
| MX (1) | MXPA04004013A (zh) |
| MY (1) | MY129741A (zh) |
| NO (1) | NO326465B1 (zh) |
| NZ (1) | NZ532716A (zh) |
| PE (1) | PE20030629A1 (zh) |
| PL (1) | PL211462B1 (zh) |
| PT (1) | PT1442023E (zh) |
| RS (1) | RS50879B (zh) |
| SA (1) | SA02230419B1 (zh) |
| SI (1) | SI1442023T1 (zh) |
| TW (2) | TWI333419B (zh) |
| UA (1) | UA82833C2 (zh) |
| UY (1) | UY27520A1 (zh) |
| WO (1) | WO2003037876A1 (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029363B2 (en) | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
| DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
| WO2005077941A2 (en) | 2004-02-11 | 2005-08-25 | Teva Pharmaceutical Industries Ltd. | Candesartan cilexetil polymorphs |
| MXPA06012702A (es) * | 2004-05-05 | 2007-04-02 | Teva Pharma | Preparacion de candesartan cilexetil de alta pureza. |
| WO2006044754A2 (en) | 2004-10-18 | 2006-04-27 | Dr. Reddy's Laboratories Ltd. | Process for preparing telmisartan |
| JP2008516001A (ja) * | 2004-11-03 | 2008-05-15 | テバ ファーマシューティカル インダストリーズ リミティド | 非晶質、および多形のフォームのテルミサルタン・ナトリウム |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| EP2151450A1 (de) * | 2008-07-29 | 2010-02-10 | Sandoz AG | Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden |
| CN102458363A (zh) | 2009-05-20 | 2012-05-16 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 替米沙坦的药物口服溶液 |
| EP2448576A2 (en) | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| EP2448575A2 (en) | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
| EP2632438A1 (en) | 2010-10-27 | 2013-09-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
| CN103619556B (zh) * | 2011-06-24 | 2016-12-07 | 本田技研工业株式会社 | 注塑成形方法及其装置 |
| MY197904A (en) | 2011-11-25 | 2023-07-24 | Adverio Pharma Gmbh | Method for producing substituted 5-fluoro-1h-pyrazolopyridines |
| WO2016065028A1 (en) | 2014-10-21 | 2016-04-28 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine |
| KR101872726B1 (ko) * | 2016-07-28 | 2018-06-29 | 주식회사 씨트리 | 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물 |
| DK3648761T3 (da) | 2017-07-07 | 2024-06-24 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan til forebyggelsen eller behandlingen af hypertension i katte |
| JP2022517610A (ja) * | 2019-01-10 | 2022-03-09 | シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド | 複素環化合物塩およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5594003A (en) * | 1991-02-06 | 1997-01-14 | Dr. Karl Thomae Gmbh | Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists |
| DE69718146T2 (de) * | 1996-02-29 | 2003-10-02 | Novartis Ag, Basel | At1 rezeptor antagonist zur anregung von apoptosis |
| DE19901921C2 (de) * | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
-
2001
- 2001-10-31 DE DE10153737A patent/DE10153737A1/de not_active Ceased
-
2002
- 2002-10-11 ES ES02777305T patent/ES2291505T3/es not_active Expired - Lifetime
- 2002-10-11 BR BR0213568-0A patent/BR0213568A/pt active Pending
- 2002-10-11 RS YUP-363/04A patent/RS50879B/sr unknown
- 2002-10-11 MX MXPA04004013A patent/MXPA04004013A/es active IP Right Grant
- 2002-10-11 PL PL367477A patent/PL211462B1/pl unknown
- 2002-10-11 JP JP2003540158A patent/JP5124076B2/ja not_active Expired - Lifetime
- 2002-10-11 AU AU2002338886A patent/AU2002338886B2/en not_active Ceased
- 2002-10-11 WO PCT/EP2002/011394 patent/WO2003037876A1/de active IP Right Grant
- 2002-10-11 CN CNB028216202A patent/CN100509789C/zh not_active Expired - Fee Related
- 2002-10-11 HU HU0402391A patent/HUP0402391A3/hu not_active Application Discontinuation
- 2002-10-11 DE DE50210719T patent/DE50210719D1/de not_active Expired - Lifetime
- 2002-10-11 CA CA2463146A patent/CA2463146C/en not_active Expired - Fee Related
- 2002-10-11 IL IL16116502A patent/IL161165A0/xx unknown
- 2002-10-11 EA EA200400479A patent/EA007596B1/ru not_active IP Right Cessation
- 2002-10-11 SI SI200230594T patent/SI1442023T1/sl unknown
- 2002-10-11 ME MEP-436/08A patent/MEP43608A/xx unknown
- 2002-10-11 KR KR1020047006317A patent/KR100929502B1/ko not_active IP Right Cessation
- 2002-10-11 EP EP02777305A patent/EP1442023B1/de not_active Expired - Lifetime
- 2002-10-11 PT PT02777305T patent/PT1442023E/pt unknown
- 2002-10-11 DK DK02777305T patent/DK1442023T3/da active
- 2002-10-11 NZ NZ532716A patent/NZ532716A/en not_active IP Right Cessation
- 2002-10-11 AT AT02777305T patent/ATE370125T1/de active
- 2002-10-28 PE PE2002001061A patent/PE20030629A1/es not_active Application Discontinuation
- 2002-10-28 UY UY27520A patent/UY27520A1/es not_active Application Discontinuation
- 2002-10-29 MY MYPI20024051A patent/MY129741A/en unknown
- 2002-10-29 TW TW091132070A patent/TWI333419B/zh not_active IP Right Cessation
- 2002-10-29 TW TW099114822A patent/TWI341200B/zh not_active IP Right Cessation
- 2002-10-30 AR ARP020104113A patent/AR037148A1/es active Pending
- 2002-11-05 SA SA02230419A patent/SA02230419B1/ar unknown
- 2002-11-10 UA UA20040503959A patent/UA82833C2/uk unknown
-
2004
- 2004-03-30 IL IL161165A patent/IL161165A/en not_active IP Right Cessation
- 2004-04-26 HR HR20040372A patent/HRPK20040372B3/xx not_active IP Right Cessation
- 2004-04-27 EC EC2004005089A patent/ECSP045089A/es unknown
- 2004-04-29 NO NO20041758A patent/NO326465B1/no not_active IP Right Cessation
- 2004-05-07 CO CO04042445A patent/CO5580785A2/es not_active Application Discontinuation
-
2005
- 2005-07-26 HK HK05106371.1A patent/HK1073841A1/xx not_active IP Right Cessation
-
2007
- 2007-10-15 CY CY20071101332T patent/CY1107504T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161165A0 (en) | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist | |
| AU2002338886A1 (en) | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist | |
| HK1139681A1 (en) | Salts of valsartan | |
| PL376575A1 (pl) | Podstawione związki heterocykliczne oraz sposoby wykorzystania | |
| EP1387680A4 (en) | AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE | |
| ZA200500680B (en) | Quinoline derivatives and their use as mycrobacterial inhibitors | |
| IL163549A0 (en) | Topiramate salts and compositions comprising and methods of making and using the same | |
| IL169336A0 (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| HK1151511A1 (zh) | 烷基化劑的製備和用途 | |
| HK1088910A1 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| HUP0401756A3 (en) | Substituted benzimidazole compounds and their use | |
| IL164698A0 (en) | Attenuation of metapneumovirus | |
| AU2003279841A8 (en) | Uses of human zven antagonists | |
| GB2413471B (en) | Tomography of curved surfaces | |
| IL169337A0 (en) | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
| HUP0401641A3 (en) | Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors | |
| IL162645A0 (en) | solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds | |
| GB0227906D0 (en) | Compounds and their use | |
| IL163605A0 (en) | Use of an inhibitor or antagonist against tissue factor | |
| SG127755A1 (en) | Imidazoline compounds | |
| IL165356A0 (en) | Preparation of 4-haloalkylkylnicotinamides | |
| PL363949A1 (en) | Substituted benzoylcyclohexenones and their use as herbicidal agents | |
| GB0207286D0 (en) | Salt | |
| GB0101128D0 (en) | Use of an LTB4 antagonist | |
| GB0204550D0 (en) | Testing effective of protection |